Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blocka...
Main Authors: | Annette M. Lim, Karda Cavanagh, Rodney J. Hicks, Luke McLean, Michelle S. Goh, Angela Webb, Danny Rischin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.656611/full |
Similar Items
-
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
by: Luke S. McLean, et al.
Published: (2022-01-01) -
Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy
by: Karda Cavanagh, et al.
Published: (2024-03-01) -
FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
by: Luke S. McLean, et al.
Published: (2021-10-01) -
Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
by: Alesha A. Thai, et al.
Published: (2021-11-01) -
Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01)